Pasithea Therapeutics Files 8-K on Shareholder Nominations

Ticker: KTTAW · Form: 8-K · Filed: Jul 11, 2025 · CIK: 1841330

Pasithea Therapeutics CORP. 8-K Filing Summary
FieldDetail
CompanyPasithea Therapeutics CORP. (KTTAW)
Form Type8-K
Filed DateJul 11, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: governance, shareholder-action

TL;DR

Pasithea Therapeutics filed an 8-K regarding shareholder nominations. Board changes might be coming.

AI Summary

Pasithea Therapeutics Corp. filed an 8-K on July 11, 2025, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing indicates that the earliest event reported was on July 10, 2025. The company is incorporated in Delaware and its principal executive offices are located in Miami Beach, Florida.

Why It Matters

This filing signals potential changes in the company's board composition or strategic direction due to shareholder involvement.

Risk Assessment

Risk Level: medium — Shareholder nominations can indicate activism or dissatisfaction, potentially leading to strategic shifts or governance changes.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report shareholder nominations pursuant to Exchange Act Rule 14a-11.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on July 10, 2025.

What is the exact name of the registrant?

The exact name of the registrant is Pasithea Therapeutics Corp.

In which state is Pasithea Therapeutics Corp. incorporated?

Pasithea Therapeutics Corp. is incorporated in Delaware.

Where are the principal executive offices of Pasithea Therapeutics Corp. located?

The principal executive offices of Pasithea Therapeutics Corp. are located at 1111 Lincoln Road, Suite 500, Miami Beach, Florida 33139.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 11, 2025 regarding Pasithea Therapeutics Corp. (KTTAW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing